Neurodegeneration with Brain Iron Accumulation (NBIA)

Neurodegeneration with Brain Iron Accumulation (NBIA)

Introduction

Neurodegeneration with Brain Iron Accumulation (NBIA) comprises a group of rare, genetically heterogeneous neurodegenerative disorders characterized by abnormal iron deposition in the brain, particularly in the globus pallidus and substantia nigra. The clinical phenotype includes progressive movement disorders and cognitive decline[@kruer2022]. NBIA disorders are part of the broader category of neurodegeneratived diseases affecting the basal ganglia, and share features with Parkinson's disease and Huntington's disease.

Epidemiology

NBIA disorders are rare, with an estimated prevalence of 1-2 per 1,000,000 individuals worldwide. However, this likely underestimates true prevalence due to underdiagnosis. PKAN (pantothenate kinase-associated neurodegeneration) is the most common subtype, accounting for approximately 35-50% of all NBIA cases[@gregory2021]. The disorders affect both males and females equally and typically present in childhood or early adolescence, though adult-onset variants exist.

Pathogenesis Flowchart

Neurodegeneration with Brain Iron Accumulation (NBIA)

Introduction

Neurodegeneration with Brain Iron Accumulation (NBIA) comprises a group of rare, genetically heterogeneous neurodegenerative disorders characterized by abnormal iron deposition in the brain, particularly in the globus pallidus and substantia nigra. The clinical phenotype includes progressive movement disorders and cognitive decline[@kruer2022]. NBIA disorders are part of the broader category of neurodegeneratived diseases affecting the basal ganglia, and share features with Parkinson's disease and Huntington's disease.

Epidemiology

NBIA disorders are rare, with an estimated prevalence of 1-2 per 1,000,000 individuals worldwide. However, this likely underestimates true prevalence due to underdiagnosis. PKAN (pantothenate kinase-associated neurodegeneration) is the most common subtype, accounting for approximately 35-50% of all NBIA cases[@gregory2021]. The disorders affect both males and females equally and typically present in childhood or early adolescence, though adult-onset variants exist.

Pathogenesis Flowchart

Major Subtypes

| Subtype | Gene | Protein | Inheritance | Key Features | Frequency |
|---------|------|---------|-------------|--------------|-----------|
| PKAN | PANK2 | Pantothenate Kinase 2 | AR | Rapid progression, eye involvement, "eye of the tiger" sign | 35-50% |
| PLAN | PLA2G6 | iPLA2-VI | AR | Dystonia, cognitive decline, iron accumulation | 20-25% |
| BPAN | WDR45 | WD40 Repeat Protein | X-linked | Developmental delay, seizures, adult-onset neurodegeneration | 5-10% |
| FA2H | FA2H | Fatty Acid 2-Hydroxylase | AR | Spastic paraplegia, ataxia, cognitive decline | 3-5% |
| MPAN | COASY/MTOR | Coenzyme A Synthetase/mTOR | AR | Late onset, psychiatric symptoms | 3-5% |
| CoPAN | COASY | Coenzyme A Synthetase | AR | Corticobasal syndrome features | Rare |
| WSSPN | WDR45B | WD40 Repeat Protein | AR | Severe developmental delay | Very rare |
| PANH | PANK2 | Pantothenate Kinase | AR | Variant PKAN presentation | Rare |

PKAN (Pantothenate Kinase-Associated Neurodegeneration)

PKAN is the most common and well-studied NBIA subtype, caused by mutations in the PANK2 gene[@zhou2020]. The disorder typically presents in early childhood with progressive dystonia, dysarthria, and cognitive decline. Classic PKAN shows the characteristic "eye of the tiger" sign on brain MRI, with central T2 hyperintensity surrounded by hypointensity in the globus pallidus. Early-onset cases progress rapidly, while late-onset variants may have slower progression.

PLAN (Phospholipase A2-Associated Neurodegeneration)

PLAN results from mutations in PLA2G6[@mori2019]. Patients typically present between ages 2-4 years with progressive gait disturbance, dystonia, and neurodevelopmental regression. Brain MRI shows iron accumulation in the globus pallidus and substantia nigra, with cerebellar atrophy in later stages. PLAN has a broader phenotype than PKAN, including early-onset dystonia-parkinsonism.

BPAN (Beta-Propeller Protein-Associated Neurogeneration)

BPAN is caused by de novo mutations in the X-linked WDR45 gene[@hayflick2021]. It is the most common X-linked NBIA disorder. Affected individuals typically present with early-onset seizures and developmental delay in childhood, followed by progressive neurodegeneration in adulthood. The "eye of the tiger" sign is less common in BPAN.

FA2H (Fatty Acid Hydroxylase-Associated Neurodegeneration)

Mutations in FA2H[@edvardson2020] cause a spectrum of disorders including hereditary spastic paraplegia (SPG35) and NBIA. Clinical features include spastic paraplegia, ataxia, seizures, and cognitive decline. Brain MRI shows iron deposition in the globus pallidus and substantia nigra, along with white matter abnormalities.

MPAN (Mitochondrial Membrane Protein-Associated Neurodegeneration)

MPAN is caused by mutations in the COASY gene[@dusi2022], which encodes Coenzyme A synthetase. It presents in adolescence or early adulthood with progressive motor symptoms including dystonia and parkinsonism. Cognitive decline and psychiatric symptoms are also common features.

Molecular Pathogenesis

Iron Dysregulation

Mutations in NBIA genes lead to dysfunction in iron metabolism pathways, causing pathological iron accumulation in the basal ganglia. The iron deposition triggers oxidative stress through Fenton chemistry, generating reactive oxygen species that damage neurons[@crigler2021]. Iron accumulation primarily occurs in the globus pallidus and substantia nigra pars reticulata, regions rich in iron-handling proteins.

Coenzyme A Metabolism

PANK2 mutations disrupt coenzyme A (CoA) biosynthesis, leading to impaired mitochondrial function and increased oxidative stress in neurons. CoA is essential for cellular metabolism, lipid synthesis, and mitochondrial function. The disruption of CoA pathways in PKAN provides a rationale for CoA-supplementation therapeutic approaches[@campellone2023].

Mitochondrial Dysfunction

Iron accumulation in NBIA leads to mitochondrial dysfunction through multiple mechanisms: oxidative stress damages mitochondrial DNA and proteins, iron overload impairs electron transport chain Complex I activity, and ferritin accumulation sequesters iron in a redox-inactive form. This creates a vicious cycle of mitochondrial damage and iron accumulation.

Clinical Features

Movement Disorders

• Progressive dystonia (most common, affecting 80-90% of patients)
• Parkinsonism with levodopa responsiveness in some subtypes
• Chorea and athetosis
• Spasticity, particularly in FA2H-related NBIA
• Tremor (less common)
• Dysarthria and dysphagia

Neuropsychiatric Symptoms

• Personality changes
• Depression and anxiety
• Behavioral disturbances
• Psychosis (more common in MPAN)
• Attention deficit and hyperactivity

Cognitive Decline

Cognitive impairment progresses in most patients, ranging from mild executive dysfunction to severe dementia. The pattern typically involves:

• Executive dysfunction (most common)
• Memory impairment
• Processing speed deficits
• Global cognitive decline in advanced stages

Ocular Findings

Retinal degeneration and optic atrophy are common in certain NBIA subtypes, particularly PKAN. Visual symptoms may include:

• Progressive visual loss
• Optic atrophy
• Retinal pigmentary changes
• Night blindness

Seizures

Seizures occur in approximately 30-50% of NBIA patients, particularly in BPAN and FA2H subtypes. seizure types include:

• Generalized tonic-clonic seizures
• Focal seizures
• Myoclonic seizures
• Infantile spasms (in early-onset cases)

Neuroimaging

MRI Findings

• T2 hypointensity in globus pallidus and substantia nigra (iron deposition)
• "Eye of the tiger" sign in PKAN (central hyperintensity surrounded by hypointensity in globus pallidus)
• Progressive brain atrophy in later stages
• Cerebellar atrophy in PLAN
• White matter abnormalities in FA2H

Iron Quantification

Quantitative susceptibility mapping (QSM) and R2* relaxometry can track iron accumulation over time and monitor treatment response. These techniques are increasingly used in clinical trials for NBIA disorders.

Additional Imaging Findings

• MR spectroscopy may show decreased N-acetylaspartate (NAA) and increased lactate
• Diffusion tensor imaging (DTI) shows reduced fractional anisotropy in affected regions
• PET imaging may show reduced FDG uptake in basal ganglia

Diagnosis

Genetic Testing

Genetic testing is the gold standard for NBIA diagnosis. Targeted gene panels for NBIA disorders are available and include:

• PANK2 sequencing
• PLA2G6 sequencing
• WDR45 sequencing
• FA2H sequencing
• COASY sequencing
• WDR45B sequencing

Clinical Diagnostic Criteria

Diagnosis is based on:

Differential Diagnosis

NBIA must be differentiated from:

• Parkinson's disease
• Huntington's disease
• Pelizaeus-Merzbacher disease
• Organic acidurias
• Other causes of basal ganglia degeneration

Treatment Approaches

Iron Chelation

Deferoxamine and deferasirox may reduce iron burden, though efficacy varies by subtype. Chelation therapy requires careful monitoring due to potential side effects:

• Auditory toxicity
• Visual toxicity
• Renal dysfunction
• Growth retardation in children

Coenzyme A Supplementation

Pantethine (a stable derivative of pantothenate) and CoA supplementation have shown benefit in some PKAN patients[@collins2022]. This approach aims to bypass the defective PANK2 enzyme. Clinical trials are ongoing.

Deep Brain Stimulation

DBS can be effective for severe dystonia in selected patients. Target regions include:

• Globus pallidus internus (GPi)
• Subthalamic nucleus
• Thalamus

Symptomatic Treatments

• Dystonia: Baclofen, benzodiazepines, botulinum toxin injections
• Parkinsonism: Levodopa/carbidopa (variable response)
• Seizures: Antiepileptic medications (individualized)
• Psychiatric symptoms: SSRIs, antipsychotics
• Nutritional support: Multivitamins, CoQ10 supplementation

Emerging Therapies

• Gene therapy: AAV-vector mediated PANK2 delivery (preclinical/early clinical)
• Small molecule PANK2 activators: In development
• Iron chelators: Newer agents with better brain penetration
• Neuroprotective agents: CoQ10, creatine, antioxidants

Clinical Trials

Several clinical trials are investigating new treatments for NBIA disorders:

Prognosis

Prognosis varies significantly by subtype and age of onset:

• Classic PKAN: Progressive decline, often wheelchair-bound by teens
• Late-onset PKAN: Slower progression, longer survival
• PLAN: Variable, often severe disability
• BPAN: Progressive cognitive and motor decline
• MPAN: Generally slower progression

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons-disease)
• PANK2 Gene
• PLA2G6 Gene
• WDR45 Gene
• [Iron Metabolism](/mechanisms/iron-metabolism-neurodegeneration)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Oxidative Stress](/mechanisms/oxidative-stress)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References